JW Pharmaceutical Corporation 001060
KRX · South Korea · Health Technology
KRW 26,650.00-500.00 (-1.84%)
Market open· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
SEOUL, South Korea, August 13, 2026--JW Pharmaceutical proved the efficacy and safety of its gout drug candidate "Epaminurad" in a Phase 3 clinical trial.
SEOUL, South Korea, June 11, 2026--JW Pharmaceutical highlighted the therapeutic potential of DDC-02 in multiple neurodevelopmental disorder models at WODC USA 2026
Gan & Lee will receive a $5m upfront payment plus up to $76.1m in milestone payments.
Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", SSE: 603087) announced the signing of an exclusive licensing agreement with JW Pharmaceutical, a leading pharmaceutical company in South Korea. Under the agreement, the two parties will collaborate on the clinical development, regulatory filing, and commercialization in South Korea of Bofanglutide Injection, a bi-weekly (once every two weeks) Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) independently discovered and develope
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.